021-51111890
购物车（）
sales@molnova.cn
EDO-S101
CAS No. 1236199-60-2
EDO-S101 ( EDO-S 101;Tinostamustine )
产品货号. M10949 CAS No. 1236199-60-2
EDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥437 | 有现货 |
|
| 5MG | ￥624 | 有现货 |
|
| 10MG | ￥1021 | 有现货 |
|
| 25MG | ￥1677 | 有现货 |
|
| 50MG | ￥2989 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称EDO-S101
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述EDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.
-
产品描述EDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat; displays potent activity in vitro in MM cell lines (IC50=1.6-4.8 uM) and ex vivo in cells isolated from MM patients; shows activity in CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice, also is the only drug with single-agent activity in the multidrug resistant Vk12653 murine model.Blood Cancer Phase 1 Clinical
-
同义词EDO-S 101;Tinostamustine
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1;HDAC2;HDAC3;HDAC6;HDAC8
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1236199-60-2
-
分子量415.36
-
分子式C19H28Cl2N4O2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 30 mg/mL
-
SMILESCN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
-
化学全称1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mehrling T, et al. Anticancer Agents Med Chem. 2016;16(1):20-8.
2. López-Iglesias AA, et al. J Hematol Oncol. 2017 Jun 20;10(1):127.
3. Besse L, et al. Blood Cancer J. 2017 Jul 28;7(7):e589.
2. López-Iglesias AA, et al. J Hematol Oncol. 2017 Jun 20;10(1):127.
3. Besse L, et al. Blood Cancer J. 2017 Jul 28;7(7):e589.
产品手册
关联产品
-
SALL4 peptide FFW
SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD.
-
Belinostat
Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
-
SKLB-23bb
SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.
